FDA approves once daily oral pill Juvmo, AbbVie's partial dopamine agonist previously known as tavapadon

A new oral medication has received marketing approval in the United States, providing another clinical pathway for managing movement symptoms. On 25 September 2026, the United States Food and Drug Administration officially licensed the drug, which many in the research community and clinical trials will remember under its chemical name tavapadon. Developed by AbbVie, the medicine will be marketed commercially under the brand name Juvmo. The manufacturer confirmed that the once daily prescription tablet is scheduled to become available across American pharmacies in October 2026. For people in the United Kingdom, the European Union, and other parts of the world, local regulatory applications remain under assessment, meaning decisions from authorities such as the MHRA and EMA are still awaited before it can be supplied internationally. Juvmo introduces a selective mechanism of action that differs from earlier classes of dopamine agonists. When dopamine levels drop, nerve circuits struggle to relay movement signals smoothly. Older dopamine treatments typically activate multiple dopamine receptors indiscriminately, which can trigger unwanted physical or behavioural side effects. Tavapadon focuses specifically on the D1 and D5 receptor subtypes. Furthermore, it operates as a partial agonist rather than a full activator. Instead of pushing the receptors into overdrive, it gently dials up their activity to restore motor stability while seeking to avoid biological overstimulation. Because the compound breaks down slowly in the body, it delivers a steady effect that requires only one dose per day. The regulatory green light is supported by the Phase III TEMPO trial programme, which evaluated the therapy across different stages of the condition. In the TEMPO one and TEMPO two trials, researchers tested tavapadon on its own in people within their first few years of diagnosis. Over twenty six weeks, participants taking the medicine achieved significant improvements in combined motor function and daily living scores compared to those on a placebo, reflecting meaningful ease in tasks such as walking, dressing, and general mobility. In the TEMPO three trial, which investigated individuals already taking levodopa who experienced daily wearing off periods, adding tavapadon increased good mobility time without troublesome involuntary movements by more than an hour each day while noticeably reducing off periods. Safety data collected throughout the studies show that the drug is generally well tolerated, though the official prescribing label notes several precautions common to dopaminergic treatments. These include possible sudden drops in blood pressure when standing, unexpected drowsiness, hallucinations, involuntary movements, and changes in impulse control such as compulsive behaviours. With its initial roll out imminent in the United States, the arrival of Juvmo gives people living with Parkinson's and their medical teams a modern, finely targeted oral option that functions both on its own in earlier stages and alongside levodopa regimens.